Histoscan-guided targeted biopsy of the prostate

Introduction. Prostate cancer is the second most commonly diagnosed malignant neoplasm in men. The development of technologies requires the study of advanced research methods, an extraordinary, new limited-invasive method for diagnosing cancer - histoscanning of the prostate. Histoscan is an innovative imaging technique that is potent of differentiating between benign and malignant areas within the examined prostate tissue. With the new “True Targeting” software, it is possible to perform a “targeted” biopsy in real time. Purpose. To determine the efficacy and safety of performing histoscan-guided targeted biopsy of the prostate. Materials and methods. The prospective study with the inclusion of data from 2501 patients examined at the Clinic of urology of the Moscow State Medical University named after A.I. Evdokimov at the Municipal Clinical Hospital named after S.I. Spasokukotsky. Results. The average age of the patients was 66 years, the level of prostate specific antigen was about 14,39 ng/ml, the volume of the prostate was 54,43 cm3. The overall incidence of prostate cancer was 53,38%, with a biopsy of 12 points - 52,1%, while with a targeted biopsy- 37,58%. Among the biopsy complications, hemospermia (Clavien-Dindo - I) was most often (33% of cases), hematuria (Clavien-Dindo - I-II) in 15% of cases. No serious complications were identified. Limitations. As restrictions, the following were identified: prostate biopsy-subject, 2501 patients - a quantitative parameter, patients with suspected prostate cancer - a qualitative indicator. Conclusion. The published results of the study showed that histoscan-guided biopsy ofthe prostate is safe, effective, and therefore has alarge potential in cancer diagnosis, as it helps both in choosing a treatment method and in planning the course of further surgery.